GMP-grade microcarrier and automated closed industrial scale cell production platform for culture of MSCs

IF 3.1 3区 生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Yuanyuan Zhang, Tao Na, Kehua Zhang, Yanping Yang, Huanye Xu, Lina Wei, Liming Xu, Xiaojun Yan, Wei Liu, Guangyang Liu, Bin Wang, Shufang Meng, Yanan Du
{"title":"GMP-grade microcarrier and automated closed industrial scale cell production platform for culture of MSCs","authors":"Yuanyuan Zhang,&nbsp;Tao Na,&nbsp;Kehua Zhang,&nbsp;Yanping Yang,&nbsp;Huanye Xu,&nbsp;Lina Wei,&nbsp;Liming Xu,&nbsp;Xiaojun Yan,&nbsp;Wei Liu,&nbsp;Guangyang Liu,&nbsp;Bin Wang,&nbsp;Shufang Meng,&nbsp;Yanan Du","doi":"10.1002/term.3341","DOIUrl":null,"url":null,"abstract":"<p>Efficient and large-scale expansion of mesenchymal stem/stromal cells (MSCs) has always been a formidable challenge to researchers in cell-based therapies and regenerative medicine. To reconcile major drawbacks of 2D planar culturing system, we innovatively developed an automated closed industrial scale cell production (ACISCP) platform based on GMP-grade microcarrier for culture of umbilical cord-mesenchymal stem/stromal cells (UCMSCs), in accordance with the criteria of stem cell bank. ACISCP system is a fully closed system, which employs different models of vivaSPIN bioreactors (CytoNiche Biotech, China) for scale-up cell culture and vivaPREP (CytoNiche Biotech, China) for automated cell harvesting and cell dosage preparation. To realize industrial scale expansion of UCMSCs, a three-stage expansion was conducted with 1 L, 5 and 15 L vivaSPIN bioreactors. Using 3D TableTrix<sup>®</sup> and ACISCP system, we inoculated 1.5 × 10<sup>7</sup> of UCMSCs into 1 L vivaSPIN bioreactor and finally scaled to two 15 L bioreactor. A final yield of 2.09 × 10<sup>10</sup> cells with an overall expansion factor of 1975 within 13 days. The cells were harvested, concentrated, washed and prepared automatically with vivaPREP. The entire process was realized with ACISCP platform and was totally enclosed. Critical quality attributes (CQA) assessments and release tests of MSCs, including sterility, safety, purity, viability, identity, stability and potency were performed accordingly. The quality of cells harvested from 3D culture on the ACISCP and conventional 2D planar culture counterpart has no significant difference. This study provides a bioprocess engineering platform, harnessing GMP-grade 3D TableTrix<sup>®</sup> microcarriers and ACISCP to achieve industrial-scale manufacturing of clinical-grade hMSCs.</p>","PeriodicalId":202,"journal":{"name":"Journal of Tissue Engineering and Regenerative Medicine","volume":"16 10","pages":"934-944"},"PeriodicalIF":3.1000,"publicationDate":"2022-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Tissue Engineering and Regenerative Medicine","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/term.3341","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 4

Abstract

Efficient and large-scale expansion of mesenchymal stem/stromal cells (MSCs) has always been a formidable challenge to researchers in cell-based therapies and regenerative medicine. To reconcile major drawbacks of 2D planar culturing system, we innovatively developed an automated closed industrial scale cell production (ACISCP) platform based on GMP-grade microcarrier for culture of umbilical cord-mesenchymal stem/stromal cells (UCMSCs), in accordance with the criteria of stem cell bank. ACISCP system is a fully closed system, which employs different models of vivaSPIN bioreactors (CytoNiche Biotech, China) for scale-up cell culture and vivaPREP (CytoNiche Biotech, China) for automated cell harvesting and cell dosage preparation. To realize industrial scale expansion of UCMSCs, a three-stage expansion was conducted with 1 L, 5 and 15 L vivaSPIN bioreactors. Using 3D TableTrix® and ACISCP system, we inoculated 1.5 × 107 of UCMSCs into 1 L vivaSPIN bioreactor and finally scaled to two 15 L bioreactor. A final yield of 2.09 × 1010 cells with an overall expansion factor of 1975 within 13 days. The cells were harvested, concentrated, washed and prepared automatically with vivaPREP. The entire process was realized with ACISCP platform and was totally enclosed. Critical quality attributes (CQA) assessments and release tests of MSCs, including sterility, safety, purity, viability, identity, stability and potency were performed accordingly. The quality of cells harvested from 3D culture on the ACISCP and conventional 2D planar culture counterpart has no significant difference. This study provides a bioprocess engineering platform, harnessing GMP-grade 3D TableTrix® microcarriers and ACISCP to achieve industrial-scale manufacturing of clinical-grade hMSCs.

gmp级微载体和自动化封闭工业规模细胞生产平台,用于培养msc
间充质干细胞(MSCs)的高效和大规模扩增一直是细胞治疗和再生医学研究人员面临的巨大挑战。为了解决二维平面培养系统的主要缺陷,我们创新开发了一种基于gmp级微载体的自动化封闭工业规模细胞生产(ACISCP)平台,用于培养脐带间充质干细胞/基质细胞(UCMSCs),符合干细胞库标准。ACISCP系统是一个完全封闭的系统,采用不同型号的vivaSPIN生物反应器(CytoNiche Biotech,中国)进行细胞放大培养,vivaPREP (CytoNiche Biotech,中国)进行自动细胞收获和细胞剂量制备。为了实现UCMSCs的工业规模扩展,采用1 L、5 L和15 L vivaSPIN生物反应器进行了三期扩展。使用3D TableTrix®和ACISCP系统,我们将1.5 × 107个UCMSCs接种到1 L vivaSPIN生物反应器中,最终缩放到2个15 L生物反应器。13天内最终产量为2.09 × 1010个细胞,总扩增因子为1975。用vivaPREP自动收集、浓缩、洗涤和制备细胞。整个过程在ACISCP平台上实现,完全封闭。相应进行MSCs的关键质量属性(CQA)评估和释放试验,包括无菌性、安全性、纯度、活力、身份、稳定性和效力。ACISCP上三维培养的细胞质量与传统二维平面培养的细胞质量无显著差异。本研究提供了一个生物工艺工程平台,利用gmp级3D TableTrix®微载体和ACISCP实现临床级hMSCs的工业规模制造。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.50
自引率
3.00%
发文量
97
审稿时长
4-8 weeks
期刊介绍: Journal of Tissue Engineering and Regenerative Medicine publishes rapidly and rigorously peer-reviewed research papers, reviews, clinical case reports, perspectives, and short communications on topics relevant to the development of therapeutic approaches which combine stem or progenitor cells, biomaterials and scaffolds, growth factors and other bioactive agents, and their respective constructs. All papers should deal with research that has a direct or potential impact on the development of novel clinical approaches for the regeneration or repair of tissues and organs. The journal is multidisciplinary, covering the combination of the principles of life sciences and engineering in efforts to advance medicine and clinical strategies. The journal focuses on the use of cells, materials, and biochemical/mechanical factors in the development of biological functional substitutes that restore, maintain, or improve tissue or organ function. The journal publishes research on any tissue or organ and covers all key aspects of the field, including the development of new biomaterials and processing of scaffolds; the use of different types of cells (mainly stem and progenitor cells) and their culture in specific bioreactors; studies in relevant animal models; and clinical trials in human patients performed under strict regulatory and ethical frameworks. Manuscripts describing the use of advanced methods for the characterization of engineered tissues are also of special interest to the journal readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信